• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Study: PET imaging agent could help predict depression drug’s efficacy

April 6, 2018 By Sarah Faulkner

Imaging agent for depression
Image courtesy of Mala Ananth

Researchers have identified a positron emission tomography imaging agent that could identify the patients that are more likely to benefit from a drug designed to treat major depressive disorder, according to a study published this month in The Journal of Nuclear Medicine.

The C-DASB tracer targets a protein, 5-HTT, found in the part of a person’s brain that is responsible for emotional processing, called the amygdala. Escitalopram, a selective serotonin reuptake inhibitor, is indicated for people with depression, but it doesn’t work for all patients. Scanning a person’s brain to measure their 5-HTT level could help doctors determine if a patient will benefit from treatment with escitalopram, the researchers reported.

“MDD is a heterogeneous disorder, which makes it extremely difficult to treat effectively,” lead author Mala Ananth, of Stony Brook University, said in prepared remarks. “Optimizing treatment is challenging and is performed by trial and error, which could result in weeks of ineffective treatment, placing a burden on patients.”

The study involved 31 healthy individuals and 26 MDD patients who were not taking medication prior to the study’s launch. All study participants received a PET scan using C-DASB and people in the MDD group received eight weeks of therapy with escitalopram.

“Using PET, we quantified the protein target of SSRIs, the serotonin transporter 5-HTT. Our results indicate that patients who found relief following escitalopram treatment had less 5-HTT protein before treatment began,” Ananth explained.

“Psychiatry currently has no objective markers to determine whether a treatment will be effective. PET imaging can fill that gap and can be used to quantify biological features that indicate a successful course of treatment. Further, these features shed light on the neurobiology of MDD needed to develop novel and more targeted therapeutics.” the researcher added.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, Imaging, Neurological, Pharmaceuticals Tagged With: National Institutes of Health

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS